

Kevin Martell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9339455/publications.pdf>

Version: 2024-02-01

31
papers

279
citations

1163117

8
h-index

996975

15
g-index

31
all docs

31
docs citations

31
times ranked

440
citing authors

#	ARTICLE	IF	CITATIONS
1	Increasing Demand on Human Capital and Resource Utilization in Radiation Therapy: The Past Decade. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 457-462.	0.8	10
2	Changing Landscape of Radiation Therapy for Advanced Cervical Cancer With a Focus on Interstitial Brachytherapy: A Canadian Practice Patterns Survey. <i>Practical Radiation Oncology</i> , 2022, 12, 145-154.	2.1	1
3	Success of targeted transperineal biopsy in patients on surveillance for grade group 1 prostate cancer. <i>Canadian Urological Association Journal</i> , 2022, 16, .	0.6	0
4	Implementation of high-dose-rate brachytherapy for prostatic carcinoma in an unshielded operating room facility. <i>Brachytherapy</i> , 2021, 20, 58-65.	0.5	1
5	Complications and side effects of high-dose-rate prostate brachytherapy. <i>Brachytherapy</i> , 2021, 20, 966-975.	0.5	5
6	Substantial lymphovascular space invasion predicts worse outcomes in early-stage endometrioid endometrial cancer. <i>Brachytherapy</i> , 2021, 20, 527-535.	0.5	14
7	MRIâ€TRUS registration methodology for TRUSâ€guided HDR prostate brachytherapy. <i>Journal of Applied Clinical Medical Physics</i> , 2021, 22, 284-294.	1.9	5
8	Clinical Outcomes from Dose-Reduced Radiotherapy to the Prostate in Elderly Patients with Localized Prostate Cancer. <i>Current Oncology</i> , 2021, 28, 3729-3737.	2.2	2
9	Excessive waitlists and delays to treatment with low-dose-rate brachytherapy predict an increased risk of recurrence and metastases in intermediate-risk prostatic carcinoma. <i>Clinical and Translational Radiation Oncology</i> , 2021, 30, 38-42.	1.7	1
10	Establishing a simulation-based education program for radiation oncology learners in permanent seed implant brachytherapy: Building validation evidence. <i>Brachytherapy</i> , 2020, 19, 812-819.	0.5	8
11	Rapid implementation of extreme hypofractionation protocols in prostate cancer using RapidPlanÂ® in response to COVID-19. <i>Radiotherapy and Oncology</i> , 2020, 151, 296-297.	0.6	4
12	Using infrared depth-sensing technology to improve the brachytherapy operating room experience. <i>Brachytherapy</i> , 2020, 19, 323-327.	0.5	1
13	Analysis of outcomes after non-contour-based dose painting of dominant intra-epithelial lesion in intra-operative low-dose rate brachytherapy. <i>Heliyon</i> , 2020, 6, e04092.	3.2	1
14	Editorial Comment to Highâ€doseâ€rate brachytherapy and hypofractionated external beam radiotherapy combined with longâ€term androgen deprivation therapy for very highâ€risk prostate cancer. <i>International Journal of Urology</i> , 2020, 27, 806-807.	1.0	0
15	PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer. <i>Gynecologic Oncology</i> , 2020, 158, 776-784.	1.4	15
16	Does ADT benefit unfavourable intermediate risk prostate cancer patients treated with brachytherapy boost and external beam radiotherapy? A propensity-score matched analysis. <i>Radiotherapy and Oncology</i> , 2020, 150, 195-200.	0.6	4
17	Comparison of CTVHR and organs at risk contours between TRUS and MR images in IB cervical cancers: a proof of concept study. <i>Radiation Oncology</i> , 2020, 15, 73.	2.7	4
18	Social Jetlag and Prostate Cancer Incidence in Albertaâ€™s Tomorrow Project: A Prospective Cohort Study. <i>Cancers</i> , 2020, 12, 3873.	3.7	7

#	ARTICLE	IF	CITATIONS
19	5-Year Outcomes of a Prospective Phase 1/2 Study of Accelerated Hypofractionated Radiation Therapy to the Prostate Bed. <i>Practical Radiation Oncology</i> , 2019, 9, 354-361.	2.1	8
20	Radiotherapy practices in postoperative endometrial cancer: A survey of the ABS membership. <i>Brachytherapy</i> , 2019, 18, 741-746.	0.5	10
21	Vaginal brachytherapy alone for patients with Stage II endometrial cancer with inner half cervical stromal invasion. <i>Brachytherapy</i> , 2019, 18, 606-611.	0.5	7
22	Results of 15â€Gy HDR-BT boost plus EBRT in intermediate-risk prostate cancer: Analysis of over 500 patients. <i>Radiotherapy and Oncology</i> , 2019, 141, 149-155.	0.6	29
23	Absolute percentage of biopsied tissue positive for Gleason pattern 4 disease (APP4) appears predictive of disease control after high dose rate brachytherapy and external beam radiotherapy in intermediate risk prostate cancer. <i>Radiotherapy and Oncology</i> , 2019, 135, 170-177.	0.6	8
24	Does Seed Migration Increase the Risk of Second Malignancies in Prostate Cancer Patients Treated With Iodine-125 Loose Seeds Brachytherapy?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1190-1194.	0.8	5
25	Exposure to radiation and medical oncology training: A survey of Canadian urology residents and fellows. <i>Canadian Urological Association Journal</i> , 2018, 12, 321-325.	0.6	5
26	Rates of Cannabis Use in Patients with Cancer. <i>Current Oncology</i> , 2018, 25, 219-225.	2.2	91
27	Radiation therapy for deep periocular cancer treatments when protons are unavailable: is combining electrons and orthovoltage therapy beneficial?. <i>Journal of Radiation Research</i> , 2018, 59, 593-603.	1.6	8
28	Multicenter Evaluation of Biochemical Relapseâ€Free Survival Outcomes for Intraoperatively Planned Prostate Brachytherapy Using an Automated Delivery System. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 895-903.	0.8	8
29	Management delays in patients with squamous cell cancer of neck node(s) and unknown primary site: a retrospective cohort study. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2017, 46, 39.	1.9	3
30	Parameters predicting for prostate specific antigen response rates at one year post low-dose-rate intraoperative prostate brachytherapy. <i>Journal of Contemporary Brachytherapy</i> , 2017, 2, 99-105.	0.9	5
31	Institutional long-term outcomes at the first Canadian center performing intraoperatively planned low-dose-rate brachytherapy alone in low- and intermediate-risk prostate cancer. <i>Brachytherapy</i> , 2017, 16, 822-830.	0.5	9